FDA Approves Biosimilars Yesafili and Opuviz, Opening New Avenues for Affordable Eye Treatments
The FDA has recently approved two new biosimilars, Yesafili (aflibercept-jbvf) by Biocon Biologics and Opuviz (aflibercept-yszy) by Samsung…
EF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…
Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
A recent report published by the American Association for Cancer Research titled Subgroup Analyses in Oncology Trials: Regulatory…